Drug delivery to the central nervous system: A review

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 6, Issue 2, 2003, Pages 252-273

  Misra, Ambikanandan ^a   Ganesh, S ^a   Shahiwala, Aliasgar ^a   Shah, Shrenik P ^b  

^a M S UNIVERSITY OF BARODA   (India)

^b MS University of Baroda   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BETA LACTAM ANTIBIOTIC; CENTRAL NERVOUS SYSTEM AGENTS; CISPLATIN; CYCLOSPORIN A; CYTOTOXIC AGENT; DIAZEPAM; DOXORUBICIN; EPIPODOPHYLLOTOXIN; ETOPOSIDE; FLUOROURACIL; GREPAFLOXACIN; HYDROXYUREA; LEVODOPA; LIPOSOME; METHOTREXATE; NANOPARTICLE; NIFLUMIC ACID; NITROSOUREA DERIVATIVE; PENICILLIN G; PENTETRAZOLE; PENTOBARBITAL; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STEROID; VALPROIC ACID; VIGABATRIN; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; ZIDOVUDINE;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR DISEASE; CONVULSION; DEGENERATIVE DISEASE; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG TARGETING; DRUG TRANSPORT; DRUG UPTAKE; EPILEPSY; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PARKINSON DISEASE; QUANTITATIVE STRUCTURE PROPERTY RELATION; REVIEW; SPINAL CORD DISEASE; VERTIGO;

BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 0141764816     PISSN: 14821826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (135)

1. Pardridge, W.M., Peptide drug delivery to the brain. Raven Press, New York, U.S.A., 1991.
2. Begley, D.J., The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system. J Pharm Pharmacol, 48:136-146, 1996.
3. Schlossauer, B. and Steuer, H., Comparative anatomy, physiology and in vitro models of the blood-brain and blood-retina barrier. Curr Med Chem, 2:175-186, 2002.
4. Crone, C., The blood-brain barrier: a modified tight epithelium, in Suckling AJ: Rumsby MG: Bradbury MWB (eds), The Blood-Brain Barrier in Health and Disease. Ellis Harwood, Chichester, pp 17-40, 1986.
5. Brightman M., Ultrastructure of brain endothelium, in Bradbury MWB (ed) Physiology and pharmacology of the blood-brain barrier. Handbook of experimental pharmacology 103, Springer-Verlag, Berlin, pp 1-22, 1992.
6. Lo, E.H., Singhal, A.B., Torchilin, V.P., and Abbott N.J., Drug delivery to damaged brain, Brain Res Rev, 38:140-148, 2001.
7. Davson, H.; Segal, M.B., Physiology of the CSF and blood- brain barriers. CRC Press, Florida, USA, 1995.
8. Brownless, J. and Williams, C.H., Peptidases, peptides and the mammalian blood-brain barrier, J Neuroche, 60:1089-1096, 1993
9. Witt KA, Gillespie TJ, Huber JD, Egleton, R.D., and Davis, T.P., Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability, Peptides, 22:2329-2343, 2001.
10. Nabeshima, S., Reese, T.S., Landis, D.M. and Brightman, M.W., Junctions in the meninges and marginal glia. J Comp Neurol, 164:2 127-169, 1975.
11. Brightman, M.W., The intracerebral movement of proteins injected into blood and cerebrospinal fluid of mice, Prog Brain Res, 29:19-40, 1968.
12. Saito, Y. and Wright, E.M., Bicarbonate transport across the frog choroid plexus and its control by cyclic nucleotides, J Physiol, 336:635-648, 1983.
13. Pardridge, W.M., Recent advances in blood brain-barrier transport. Annu Rev Pharmacol Toxicol, 28:25-39, 1988.
14. Cornford, E.M., Braun, L.D., Oldendorf, W.H. and Hill, M.A., Comparison of lipid-mediated blood-brain barrier penetrability in neonates and adults. Am J Physiol, 243:C161-C168, 1982.
15. Siegal, T. and zylber-Katz, E., Strategies for increasing drug delivery to the brain: focus on brain lymphoma, Clin Pharmacokinet, 41:171-186, 2002.
16. Cole, S.P.C., Bhardwaj, G., Gerlach, J.H., McKemzie, J.G., Grant, C.E., Almquist, K.C., Stewart, A.J., Kurz, E.U., Duncan, A.M.V. and Deeley, R.G., Over expression of a transporter gene in a mulitdrug-resistant human lung cancer cell line. Science, 258:1650-1654, 1992.
17. Taylor, E.M., The impact of efflux transportersin the brain on the development of drugs for CNS disorders, Clin Pharmacokinet, 41:81-92, 2002.
18. Sadeque, A.J., Wandel, C., He, H., Shah, S., and Wood. A.J., Increased drug delivery to the brain by P-glycoprotein inhibition, Clin Pharmacol Ther, 68:231-237, 2000.
19. Salvolainen, J., Edwards, J.E., Morgan, M.E., McNamara, P.J., and Anderson, B.D., Effects of a P-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiency virus drugs administered in combination in rats, Drug Metab Dispos, 30:479-482, 2002.
20. Fellner, S., Bauer, B., Miller, D.S., Schaffrik, M., Fankhanel, M., Spruss, T., Bernhardt, G., Graeff, C., Farber, L., Gschaidmeier, H., Buschauer, A., and Fricker, G., Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo, J Clin Invest, 110:1309-1318, 2002.
21. Gupta, S.P., QSAR studies on drugs acting at the central nervous system. Chem Rev, 89:1765-1800, 1989.
22. Hansch, C., Leo, A. and Hoekman, D., Exploring QSAR. Hydrophobic, Electronic, and Steric Constants. American Chemical Society, Washington, DC, 1995.
23. van de Waterbeemd, H., Smith, D.A., Beaumont, K. and Walker, DK., Property-based design: optimization of drug absorption and pharmacokinetics. J Med Chem, 44:1313-1333, 2001.
24. Lin, J.H. and Lu, A.Y., Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev, 49:403-449, 1997.
25. Lewis, D.F.V. and Dickins, M., Substrate SARs in human P450s. Drug DIscov Today, 7:918-925, 2002.
26. Oldendorf, W.H., Measurement of brain uptake of radiolabeled substances using a tritiated water internal standard. Brain Res, 24:1629-1639, 1970.
27. Pardridge, W.M., Triguero, D., Yang, J. and Cancilla, P.A., Comparison of in-vitro and in-vivo models of drug transcytosis through blood-brain barrier. J Pharm Exp Ther, 253:884-891, 1990.
28. Levin, V.A., Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem, 23:682-684, 1980.
29. Cornford, E.M. and Oldendorf, W.H., Epilepsy and the blood- brain barrier. Adv Neurol 44:787-812, 1986.
30. Abraham, M.H., Chadha, H.S. and Mitchell, R.C., Hydrogen bonding. 33. Factors that influence the distribution of solutes between blood and brain. J Pharm Sci, 83:1257-1268, 1994.
31. Sippl, W., Computational approaches for the prediction of blood-brain barrier permeation, Curr Med Chem, 2:212-227, 2002.
32. de Boer, A.G. and Gaillard, P.J., In vitro models of blood-brain barrie: when to use which, Curr Med Chem, 2:203-209, 2002.
33. Mertsch, K. and Maas, J., Blood-brain barrier penetration and drug development from an industrial point of view, Curr Med Chem, 2:189-209, 2002.
34. Buchwald, P. and Bodor, N., Computer-aided drug design: the role of quantitative structure-property, structure-activity and structure-metabolism relationships (QSPR, QSAR, QSMR), Drugs Future, 27:577-588, 2002.
35. Kerns, E.H., Hightroughput physicochemical profiling for drug discovery. J Pharm Sci, 90:1838-1858, 2001.
36. Kakee, A., Terasaki, T. and Sugiyama, Y., Brain efflux index as a novel method of solute analyzing efflux transport at the blood-brain barrier. J Pharmacol Exp Ther, 277:1550-1559, 1996.
37. Begley, D.J., Squires, L.K., Zlokovic, B.V., Mitrovic, D.M., Hughes, C.C.W., Revest, P.A. and Greenwood, J., Permeability of the blood-brain barrier to the immunosuppressive cyclic peptide cyclosporine A. J Neurochem ,55:1222-1230, 1998.
38. Jaehde, U., Langemeijer, M.W.E., de Boer, A.G. and Breimer, D.D., Cerebrospinal fluid transport and deposition of the quinolones ciprofloxacin and pefloxacin. J Pharmacol Exp Ther, 263(3):1140-1146, 1992.
39. de lange, E.C.M., de Boer, A.G. and Breimer, D.D., Monitoring in-vivo BBB drug transport: CSF sampling, the unit impulse response method and, with special reference, intracerebral microdialysis. STP Pharm Sci, 7(1):17-28, 1997.
40. Terasaki, T., Deguchi, Y., Kasama, Y., Pardridge, W.M. and Tsuji, A., Determination of in vivo steady-state unbound drug concentration in the brain interstitial fluid by microdialysis, Int J Pharm, 81:143-152, 1992.
41. Menacherry, S., Hubert, W. and Justice, J.B., In vivo calibration of microdialysis probes for exogenous compounds, Anal Chem, 64:577-583, 1992.
42. Tewes, B., Franke, H., Hellwig, S., Hoheisel, D., Decker, S., Griesche, D., Tilling, T., Wegener, J. and Galla, H.J., Preparation of endothelial cells in primary cultures obtained from the brains of 6-month old pigs, in de Boer AG: Sutanto W (eds), Tramsport across the blood-brain barrier: In-vitro and in-vivo techniques. Academic publishers, Amsterdam, Harwood, pp 91-97, 1997.
43. Gath, U., Hakvoort, A., Wegener, J., Decker, S. and Galla, H.J., Porcine choroids plexus cells in culture: Expression of polarized phenotype, maintenance of barrier properties and apical secretion of CSF-components. Eur J Cell Biol, 74:68-78, 1997.
44. Erben, M., Decker, S., Franke, H. and Galla, H.J., Electrical resistance measurements on cerebral capillary endothelial cells: A new technique to study small surfaces. J Biochem Biophys Methods, 30:227-238, 1995.
45. Wegener, J., Sieber, M. and Galla, H.L., Impedance analysis of epithelial and endothelial cell monolayers cultured on gold surfaces. J Biochem Biophys Methods, 32:151-170, 1996.
46. Hurst, R.D. and Fritz, I.B., Properties of an immortalized vascular endothelial/glioma cell coculture model of the blood-brain barrier. J Cell Physiol, 167:81-88, 1996.
47. Dehauck, M.P., Dehouck, B., Schluep, C., Lemaire, M. and Cecchelli, R., Drug transport to the brain: comparison between in-vitro and in-vivo models of the blood-brain barrier. Eur J Pharm Sci, 3:357-365, 1995.
48. Habgood, M.D., Begley, D.J. and Abbott, N.J., Determinants of passive drug entry into the central nervous system, Cell Mol Neurobiol, 20:231-253, 2000.
49. Thorne, R.G. and Frey II, W.H., Delivery of neurotropic factore to the central nervous system: pharmacokinetic consideration, Clin Pharmacokinet, 40:907-946, 2001.
50. Filmore, D., Breeching the blood-drain barrier, Modern Drug Discov, 5:22-27, 2002.
51. Madrid, Y., Langer, L.F., Brem, H. and Langer, R., New directions in the delivery of drugs and other substances to the central nervous system. Adv Pharmacol, 22:299-324, 1991.
52. Crivori, P., Cruciani, G. and Carrupt P., Predicting blood-brain barrier permeation from three-dimensional molecular structure, J Med Chem, 39:4750-4755, 2000.
53. Iyer, M., Mishra, R. and Han, Y., Predicting blood-brain barrier partitioning of organic molecules using membrane-interaction QSAR analysis, Pharm Res, 19:1611-1621, 2002.
54. Huwyler, J., Wu, D. and Pardridge, W.M., Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci, USA, 93:14164-14169, 1996.
55. Huwyler, J., Yang, J. and Pardridge, W.M., Targeted delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat. J Pharmacol Exp Ther, 282:1541-1546, 1997.
56. Deglon, N., Heyd, B., Tan, S.A., Joseph, J.M., Zurn, A.D. and Aebischer, P., Central nervous system delivery of recombinant ciliary neurotrophic factor by polymer encapsulated differentiated C2C12 myoblasts. Hum Gene Ther, 7:2135-2146, 1996.
57. Maysinger, D. and Morinville, A., Drug delivery to the nervous system. Trends Biotechnol, 15:410-418, 1997.
58. Bodor, N. and Kaminski, J.J., Prodrugs and site-specific chemical delivery systems. Annu Rep Med Chem, 22:303-313, 1987.
59. Lambert, D.M., Rationale and applications of lipids as prodrug carriers. EurJ Pharm Sci, 11:S15-27, 2000.
60. Han, H.k and Amidon, G.L., Targeted prodrug design to optimize drug delivery, AAPS PharmSci, 2:E6, 2000.
61. Bodor, N. and Buchwald, P., Drug targeting via retrometabolic approaches. Pharmacol Ther 76:1-27, 1997.
62. Palomino, E., Kessel, D. and Horwitz, J.P., A dihydropyridine carrier system for sustained delivery of 1′, 3′-dideoxynucleosides to the brain. J Med Chem, 32:622-625, 1989.
63. Somogyi, G., Nishitani, S., Nomi, D., Buchwald, P., Prokai, L. and Bodor, N., Targeted drug delivery to the brain via phosphonate derivatives. I: Design, synthesis, and evaluation of an anionic chemical delivery system for testosterone. Int J Pharm, 166:15-26, 1998.
64. Boder, N., Prokai, L. and Wu, W-M., A strategy for delivering peptides into the central nervous system by sequential metabolism, Science, 257:1698-1700, 1992.
65. Bodor, N. and Prokai, L., Molecular packaging: peptide delivery to the central nervous system by sequential metabolism, in Taylor M: Amidon G (eds), Peptide-Based Drug Design: Controlling Transport and Metabolism. American Chemical Society, Washington, DC, pp 317-337, 1995.
66. Chen, P., Bodor, N., Wu, W-M., and Prokai, L., Strategies to target kyotorphin analogues to the brain, J Med Chem, 41:3773-3781, 1998.
67. Wu, J., Yoon, S-H. Wu, W-M., and Bodor, N., Synthesis and biological evaluation of a brain targeted chemical delivery system of [Nva2]-TRH, J pharm Pharmacol, 54:945-950, 2002.
68. Bodor, N., Farag, H.H. and Brewster, M.E., Site-specific sustained release of drugs to the brain. Science, 214(18):1370-1372, 1981.
69. Bodor, N., Prokai, L., Wu, W.M., Farag, H.H., Jonnalagadda, S., Kawamura, M. and Simpkins, J., A strategy for delivering peptides into the central nervous system by sequential metabolism. Science, 257:1698-1700, 1992.
70. Pardridge, W.M., Transport of small molecules through the blood-brain barrier: biology and methodology. Adv Drug Deliv Rev, 15:5-36, 1995.
71. Bergley, D.J., The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system. J Pharm Pharmacol, 48:136-146, 1996.
72. Banks, W.A., Audus, K. and Davis, T.P., Permeability of the blood-brain barrier to peptides: an approach to the development of therapeutically useful analogs. Peptides, 13:1289-1294, 1992.
73. Takada, Y., Vistica, D.T., Greig, N.H., Purdon, D., Rapoport, S.I. and Smith, Q.R., Rapid high-affinity transport of a chemotherapeutic amino acid across the blood-brain barrier. Cancer Res, 52:2191-2196, 1992.
74. Pardridge, W.M., Vector-mediated drug delivery to the brain. Adv Drug Deliv Rev, 36:299-321, 1999
75. Pardridge, W.M., Drug and gene targeting to the brain with molecular Trojan horses, Nat Rev Drug Discov, 1:131-139, 2002.
76. Pardridge, W.M., Peptide Drug Delivery to the Brain. Raven Press, NY, pp 1-357, 1991.
77. Bickel, U., Yoshikawa, T., Landaw, E.M., Faull, K.F. and Pardridge, W.M., Pharmacologic effects in-vivo in brain by vector- mediated peptide drug delivery. Proc Natl Acad Sci, 90:2618-2622, 1993.
78. Lodish, H.F. and Kong, N., The secretory pathway is normal in dithiothreitol- treated cells, but disulfide-bonded proteins are reduced and reversibly retained in the endoplasmic reticulum. J Biol Chem, 268:20598-20605, 1993.
79. Yoshikawa, T. and Pardridge, W.M., Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody the transferrin receptor. J Pharmacol Exp Ther, 263:897-903, 1992.
80. Pardridge, W.M., Receptor-mediated peptide transport through the blood-brain barrier. Endocrine Rev, 7:314-330, 1986.
81. Golden, P.L., Maccagnan, T.J. and Pardridge, W.M., Human blood-brain barrier leptin receptor: Binding and endocytosis in isolated human brain microvessels. J Clin Invest, 99:14-18, 1997.
82. Tamai, I., Sai, Y., Kobayashi, H., Kamata, M., Wakamiya, T. and Tsuji, A., Structure-internalization relationship for adsorptive-mediated endocytosis of basic peptides at the blood-brain barrier. J Pharmacol Exp Ther, 280:410-415, 1997.
83. Kreuter, J., Alyautdin, R.N., Kharkevich, D.A. and Ivanov, A.A., Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res, 674:171-174, 1995.
84. Kreuter, J., Nanoparticlate systems for brain delivery of drugs, Adv Drug Deliv Rev, 47:65-81, 2001.
85. Kreuter, J., Transport of drugs across the blood-brain barrier by nanoparticles, Curr Med Chem, 2:241-249, 2002.
86. Dehouck, B., Fenart, C., Dehouck, M.P., Pierce, A., Torpier, G. and Cecchelli, R., A new function for thr LDL receptor: Transcytosis of LDL across the blood-brain barrier. J Cell Biol, 138:887-889, 1997.
87. Luck, M., Plasma protein adsorption als Moglicher Schlusselfaktor fur eine kontrollierte Arzneistoffapplikation mit partikularen Tragern. Ph. D. Thesis, Freie Universitat Berlin, pp 130-154, 1997.
88. Zordan-Nudo, T., Ling, V., Liv, Z. and Georges, E., Effect of nonionic detergents on P-glycoprotein drug binding and reversal of multidrug resistance. Cancer Res, 53:5994-6000, 1993.
89. Olivier, J-C., Fenart, L., Chauvet, R., Pariat, C., Cecchelli, R., and Couet, W., Indirect evidence that drug brain targeting using polysorbate-80 coated polybutylcyanoacrylate nanoparticles is related to toxicity, Pharm Res, 16:1836-1842, 1999.
90. Neuwelt, E.A. and Dahlborg, S.A., Blood-brain barrier disruption in the treatment of brain tumors: clinical implications, in Neuwelt EA (ed), Implications of the Blood Brain Barrier and its Manipulation: Clinical Aspects. Vol. 2, Plenum Press, New York, pp 195-262, 1989.
91. Neuwelt, E.A., Wiliams, P.C., Mickey, B.E., Frenkel, E.P. and Henner, W.D., Therapeutic dilemma of disseminated CNS minoma and the potential of increased platinum-based chemotherapy delivery with osmotic blood-brain barrier disruption. Pediatr Neurosurg 21:16-22, 1994.
92. Doran, S.E., Ren, X.D., Betz, A.L., Pagel, M.A., Neuwelt, E.A., Roessler, B.J. and Davidson, B.L., Gene expression from recombinant viral vectors in the central nervous system after blood-brain barrier disruption. Neurosurgery, 36:965-970, 1995.
93. Neuwelt, E.A., Weissleder, R., Nilaver, G., Kroll, R.A., Roman-Goldstein, S., Szumowski, J., Pagel, M.A., Jones, R.S., Remsen, L.G. and McCormick, C.I., Delivery of virus-sized iron oxide particles to rodent CNS neurons. Neurosurgery, 34:777-784, 1994.
94. Hiesiger, E.M., Voorhies, R.M., Basler, G.A., Lipschutz, L.E., Posner, and Shapiro, W.R., Opening the blood-brain and blood-tumor barriers in experimental rat brain tumors: the effect of intracarotid hyperosmolar mannitol on capillary permeability and blood flow. Ann Neurol, 19:50-59, 1986.
95. Dahlborg, S.A., Henner, W.D., Crossen, J.R., Tableman, M., Petrillo, A., Braziel, R. and Neuwelt, E.A., Non-AIDS primary CNS lymphoma: first example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without phosphoro-cognitive loss and without radiotherapy. Cancer J Sci Am, 2:166-174, 1996.
96. Kaya, M., Chang, L., Truong, A. and Brightman, M.W., Chemical induction of fenestrae in vessels of the blood-brain barrier. Exp Neurol, 142:6-13, 1996.
97. Neuwelt, E.A., Barnett, P.A., Hellstrom, K.E., Hellstrom, I., McCormick, C.I. and Ramsey, F.L., Effect of blood-brain barrier disruption on intact and fragmented monoclonal antibody localization in intracerebral lung carcinoma xenografts. J Nucl Med, 35:1831-1841, 1994.
98. Kroll, R.A. and Neuwelt, E.A., Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means, Neurosurgery, 42:1083-1099, 1998.
99. Rapoport, S.I., Osmotic opening of blood-brain barrier: principles, mechanism and therapeutic applications, Cell Mol Neurobiol, 20:217-230, 2000.
100. Miller, G., Breaking down barriers, Science, 297:1116-1118, 2002.
101. Chio, C.C., Baba, T. and Black, K.L., Selective blood-tumor pro-barrier disruption by leukotrienes. J Neurosurg, 77:407-410, 1992.
102. Black, K.L., Baba, T. and Pardridge, W.M., Enzymatic barrier protects brain capillaries from leukotriene C4. J Neurosurg, 81(5):745-751, 1994.
103. Matsukado, K., Inamura, T., Nakano, S., Fukui, M., Bartus, R.T. and Black, K.L., Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of the bradykinin analog, RMP-7. Neurosurgery, 39:125-133, 1996.
104. Abbott, N.J. and Romero, I.A., Transporting therapeutics across the blood-brain barrier. Mol Med Today, 2:106-113, 1996.
105. Emerich, D.F., Dean, R.L., and Osborn, C., Bartus, R. T., The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood-brain barrier: from concept to clinical evaluation, Clin Pharmacokinet, 40:105-123, 2001.
106. Buchwald, P. and Bodor, N., A simple, predictive, structure-based skin permeability model, J Pharm Pharmacol, 53:1087-1098, 2001.
107. Krewson, C.E., Klarman, M.L. and Saltzman, W.M., Distribution of nerve growth factor following direct delivery to brain interstitium, Brain Res, 680:196-206, 1995.
108. Newcomb, R., Abbruscato, T.J., Singh, T., Nadasdi, L., Davis, T.P., and Miljanich, G., Bioavailability of Ziconotide in brain: influx from blood, stability and diffusion, Peptides, 21:491-501, 2000.
109. Harbaugh, R.E., Saunders, R. L. and Reeder, R.F., Use of implantable pumps for central nervous system drug infusions to treat neurological disease. Neurosurgery, 23(6):693-698, 1988.
110. Blasberg, R.G., Patlak, C. and Fenstermacher, J.D., Intrathecal chemotherapy: Brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther, 195:73-83, 1975.
111. Huang, T.Y., Arita, N., Hayakawa, T., and Ushio, Y., ACNU, MTX and 5-FU penetration of rat brain tissue and tumors, J Neurooncol, 45:9-17, 1999.
112. Thorne, R.G., Emory, C.R., Ala, T.A. and Fery, W.H., Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res, 692(1-2):278-282, 1995.
113. Born, j., Lange, T. and Kern, W., Sniffing neuropeptides: a transnasal approach to the human brain, Nat Neurosci, 5:514-516, 2002.
114. Illum, L., Nasal drug delivery: new development strategies, Drug Discov Today, 7:1184-1189, 2002.
115. Bobo, R.H., Laske, D.W., Akbasak, A., Morrison, P.F., Dedrick, R.L. and Oldfield, E.H., Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U.S.A., 91:2076-2082, 1994.
116. Neuwelt, E.A., Kroll, R.A., Pagel, M.A., Muldoon, L.L and Roman Goldstein, S., Increasing volume of distribution to the brain with interstitial infusion: dose, rather than convection, might be the most important factor. Neurosurgery, 38(4):1129-1145, 1996.
117. Yaksh, T.L., Provencher, J.C., Rathbun, M.L., Myers, R.R., Powell, H., Richter, P. and Kohn, F.R., Safety assessment of encapsulated morphine delivered epidurally in a sustained-release multivesicular liposome preparation in dogs. Drug Deliv, 7(1):7-36, 2000.
118. Brem, H. and Langer, R., Polymer based drug delivery to the brain. Sci Med, 3(4):1-11, 1996.
119. Brem, H. and Gabikian, P., Biodegradable polymer implants to treat brain tumors, J Control Release, 74:63-67, 2001.
120. Fung, L.K., Ewend, M.G., Sills, A., Sipos, E.P., Thompson, R., Watts, M., Colvin, O.M., Brem, H. and Saltzman, W.M., Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res, 58(4):672-684, 1998.
121. Dang, W., Colvin, O.M., Brem, H. and Saltzman, W.M., Covalent coupling of methotrexate dextran enhances the penetration of cytotoxicity into a tissue like matrix. Cancer Res, 54:1729-1735, 1994.
122. Hanes, J., Batycky, R.P., Langer, R. and Edwards, D.A., A theoretical model of erosion and macromolecular drug release from biodegrading microspheres. J Pharm Sci, 86(12):1464-1477, 1997.
123. Jean-Pierre, B., Nathalie, F., Marie-Claire, V.J. and Philippe, M., Development of Microspheres for neurological disorders: From basics to clinical applications. J Controlled Release, 65(1-2):285-296, 2000.
124. Couvreur, P., Dubernet, C. and Puisieux, F., Controlled drug delivery with nanoparticles: Current possidilities and future trends. Eur J Pharm Biopharm, 41:2-13, 1995.
125. Pilar, C., Bruno, G., Helene, C., Didier, D., Jean, A., Jene-Pierre, N., Dominique, G., Elias, F., Jean, A.P. and Patrick, C., Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res, 18(8):1157-1166, 2001.
126. Joerg, D., Frank, M.P., Bernhard, S.A. and Ulrike, S., Influence of nanoparticles on the brain-to-serum distribution and the metabolism of valproic acid in mice. J Pharm Pharmacol, 562:1043-1047, 2000.
127. Leigh, K., Elisevich, K. and Rogers, K.A., Vascularization and microvascular permeability in solid versus cell-suspension embryonic neural grafts. J Neurosurg, 81(2):272-283, 1994.
128. Lal, B., Indurti, R.R., Couraud, P.O., Goldstein, G.W. and Laterra, J., Endothelial cell implantation and survival within experimental gliomas. Proc Natl Acad Sci U.S.A., 91(21):9695-9699, 1994.
129. Snyder, E.Y. and Senut, M.C., The use of nonneuronal cells for gene delivery. Neurobiol Dis, 4(2):69-102, 1997.
130. Yurek, D.M. and Sladek, J.R., Dopamine cell replacement: Parkinson's disease. Annu Rev Neurosci, 13:415-440, 1990.
131. Raffel, C., Culer, K., Kohn, D., Nelson, M., Siegel, S., Gillis, F., Link, C.J., Villablanca, J.G. and Anderson, W.F., Gene therapy for the treatment of recurrent pediatric malignant astrocytomas with in-vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system. Hum Gene Ther, 5(7):863-890, 1994.
132. Zlokovic, B.V. and Apuzzo, M.L., Cellular and molecular neurosurgery: pathways from concept to reality--part II: vector systems and delivery methodologies for gene therapy of the central nervous system. Neurosurgery, 40(4):805-812, 1997.
133. Lockman, P.R., Mumper, R.J., Kahn, M.A. and Allen, D.D, Nanoparticle technology for drug delivery across the blood-brain barrier, Drug Dev Ind Pharm, 28(1):1-12, 2002.
134. Oyewumi, M.O. and Mumper, R.J., Gadolinium-loaded nanoparticles engineered from microemulsion templates. Drug Dev Ind Pharm, 28(3):317-28, 2002.
135. Rohlff, C. and Southan, C., Proteomic approaches to central nervous system disorders. Curr Opin Mol Ther, 4:251-258, 2002.